{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:59:35Z","timestamp":1791874775831,"version":"4.3.4"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T00:00:00Z","timestamp":1630886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>To date, immune check-point inhibitors (ICIs), particularly inhibitors of programmed cell death-1 (PD-1) and PD ligand-1 (PD-L1) have become prominent in cancer treatment and also improved life expectancy of cancer patients. As key regulators of PD-1\/PD-L1 axis, the recruitment of tumor-associated macrophages (TAMs) enhances aggressive and invasive properties of tumors in immunosuppressive tumor microenvironment (TME) and promotes epithelial-mesenchymal transition (EMT). The aims of the study were first to characterize the critical links among PD-L1, TME and EMT process and, further, to explore the sensitivity of different chemical agents to different PD-L1 expression groups. Bioinformatical analysis revealed that PD-L1 was highly expressed in OSCC and higher PD-L1 expression correlated with worse survival in patients. Notably, PD-L1 was positively correlated with macrophages infiltration and EMT markers gene expression. Moreover, patients in the PD-L1<jats:sup>high<\/jats:sup> group were at a significant chance of benefiting from ICI treatment and they also showed higher sensitivity to the chemical drugs (olaparib, paclitaxel, docetaxel, and pazopanib). These findings implicate PD-L1 could serve as a novel target for prognostic and therapeutic approaches in OSCC patients; PD-L1-mediated immune evasion might be attributable to the infiltration of macrophages, resulting EMT progress; Chemical agents in combination with PD-L1 inhibitor could be served as personalized treatment plan for OSCC patients so as to maximize patient benefit.<\/jats:p>","DOI":"10.3389\/fimmu.2021.693881","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T05:31:34Z","timestamp":1630906294000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["PD-L1-Mediated Immunosuppression in Oral Squamous Cell Carcinoma: Relationship With Macrophage Infiltration and Epithelial to Mesenchymal Transition Markers"],"prefix":"10.3389","volume":"12","author":[{"given":"Tiantian","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caijin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renchuan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangzhi","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaozhi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3310","article-title":"Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas","volume":"21","author":"Seiwert","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70002-6","article-title":"Erlotinib and Bevacizumab in Patients With Recurrent or Metastatic Squamous-Cell Carcinoma of the Head and Neck: A Phase I\/II Study","volume":"10","author":"Cohen","year":"2009","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1146\/annurev.immunol.021908.132544","article-title":"Immune Therapy for Cancer","volume":"27","author":"Dougan","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The Blockade of Immune Checkpoints in Cancer Immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-Associated B7-H1 Promotes T-Cell Apoptosis: A Potential Mechanism of Immune Evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2762","article-title":"A Rheostat for Immune Responses: The Unique Properties of PD-1 and Their Advantages for Clinical Application","volume":"14","author":"Okazaki","year":"2013","journal-title":"Nat Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies With Curative Potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"B8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The Future of Immune Checkpoint Therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30066-3","article-title":"Safety and Clinical Activity of Pembrolizumab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-012): An Open-Label, Multicentre, Phase 1b Trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)31999-8","article-title":"Pembrolizumab Versus Methotrexate, Docetaxel, or Cetuximab for Recurrent or Metastatic Head-and-Neck Squamous Cell Carcinoma (KEYNOTE-040): A Randomised, Open-Label, Phase 3 Study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e1315488","DOI":"10.1080\/2162402X.2017.1315488","article-title":"PD-L1 and Epithelial-Mesenchymal Transition in Circulating Tumor Cells From Non-Small Cell Lung Cancer Patients: A Molecular Shield to Evade Immune System","volume":"6","author":"Raimondi","year":"2017","journal-title":"Oncoimmunology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response Biomarkers, and Combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci Transl Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.Epi-07-2893","article-title":"Gene Expression Profiling Identifies Genes Predictive of Oral Squamous Cell Carcinoma","volume":"17","author":"Chen","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: The Next Generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-9-516","article-title":"Establishing an Adjusted P-Value Threshold to Control the Family-Wide Type 1 Error in Genome Wide Association Studies","volume":"9","author":"Duggal","year":"2008","journal-title":"BMC Genomics"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-17-0307","article-title":"TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells","volume":"77","author":"Li","year":"2017","journal-title":"Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.10.003","article-title":"Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer","volume":"39","author":"Bindea","year":"2013","journal-title":"Immunity"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3337","article-title":"Robust Enumeration of Cell Subsets From Tissue Expression Profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: Gene Set Variation Analysis for Microarray and RNA-Seq Data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinf"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2004.09.015","article-title":"The Chemokine System in Diverse Forms of Macrophage Activation and Polarization","volume":"25","author":"Mantovani","year":"2004","journal-title":"Trends Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","article-title":"Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines","volume":"41","author":"Murray","year":"2014","journal-title":"Immunity"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nos116","article-title":"The Molecular Profile of Microglia Under the Influence of Glioma","volume":"14","author":"Li","year":"2012","journal-title":"Neuro Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"5587","DOI":"10.1038\/s41467-019-13441-6","article-title":"Mapping Lung Cancer Epithelial-Mesenchymal Transition States and Trajectories With Single-Cell Resolution","volume":"10","author":"Karacosta","year":"2019","journal-title":"Nat Commun"},{"key":"B25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12967-020-02697-y","article-title":"A Novel Immune Classification Reveals Distinct Immune Escape Mechanism and Genomic Alterations: Implications for Immunotherapy in Hepatocellular Carcinoma","volume":"19","author":"Liu","year":"2021","journal-title":"J Transl Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T Cell Dysfunction and Exclusion Predict Cancer Immunotherapy Response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks1111","article-title":"Genomics of Drug Sensitivity in Cancer (GDSC): A Resource for Therapeutic Biomarker Discovery in Cancer Cells","volume":"41","author":"Yang","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-0721-z","article-title":"Large-Scale Public Data Reuse to Model Immunotherapy Response and Resistance","volume":"12","author":"Fu","year":"2020","journal-title":"Genome Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/neuonc\/nov172","article-title":"PD-L1 Expression and Prognostic Impact in Glioblastoma","volume":"18","author":"Nduom","year":"2016","journal-title":"Neuro Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.3390\/cancers13092118","article-title":"Prognostic Role of Plasma PD-1, PD-L1, Pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival","volume":"13","author":"Fanale","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy264","article-title":"Phase III, Randomised Trial of Avelumab Versus Physician's Choice of Chemotherapy as Third-Line Treatment of Patients With Advanced Gastric or Gastro-Oesophageal Junction Cancer: Primary Analysis of JAVELIN Gastric 300","volume":"29","author":"Bang","year":"2018","journal-title":"Ann Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of Inflammatory Response With B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Transl Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-12-2606","article-title":"PD-1-Expressing Tumor-Infiltrating T Cells are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer","volume":"73","author":"Badoual","year":"2013","journal-title":"Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.pathol.2017.04.004","article-title":"PD-L1 Expression Predicts Longer Disease Free Survival in High Risk Head and Neck Cutaneous Squamous Cell Carcinoma","volume":"49","author":"Roper","year":"2017","journal-title":"Pathology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"JCO1800632","DOI":"10.1200\/JCO.18.00632","article-title":"Phase Ib\/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma","volume":"36","author":"Davar","year":"2018","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological Analysis Reveals a PD-L1-Associated Microenvironmental Niche for Reed-Sternberg Cells in Hodgkin Lymphoma","volume":"130","author":"Carey","year":"2017","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-17-0537","article-title":"Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation","volume":"6","author":"Hartley","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00421","article-title":"Macrophage Polarization in the Development and Progression of Ovarian Cancers: An Overview","volume":"9","author":"Cheng","year":"2019","journal-title":"Front Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3390\/ijms19041005","article-title":"Role of Macrophages in Brain Tumor Growth and Progression","volume":"19","author":"Guadagno","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.18632\/aging.103653","article-title":"Long non-Coding RNA SNHG12 Promotes Immune Escape of Ovarian Cancer Cells Through Their Crosstalk With M2 Macrophages","volume":"12","author":"Qian","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0398-5","article-title":"Prognostic Impact of CD8 and Programmed Death-Ligand 1 Expression in Patients With Resectable Non-Small Cell Lung Cancer","volume":"120","author":"Kim","year":"2019","journal-title":"Br J Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20082173","article-title":"Activated Monocytes in Peritumoral Stroma of Hepatocellular Carcinoma Foster Immune Privilege and Disease Progression Through PD-L1","volume":"206","author":"Kuang","year":"2009","journal-title":"J Exp Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20112738","article-title":"Cancer Immunoediting by the Innate Immune System in the Absence of Adaptive Immunity","volume":"209","author":"O'Sullivan","year":"2012","journal-title":"J Exp Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00065708","article-title":"Macrophages Within NSCLC Tumour Islets are Predominantly of a Cytotoxic M1 Phenotype Associated With Extended Survival","volume":"33","author":"Ohri","year":"2009","journal-title":"Eur Respir J"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100558","article-title":"A Critical Role for Macrophages in Promotion of Urethane-Induced Lung Carcinogenesis","volume":"187","author":"Zaynagetdinov","year":"2011","journal-title":"J Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1016\/s0140-6736(15)60402-0","article-title":"Can Macrophages Within the Microenvironment of Locally Invasive Rectal Cancers Predict Response to Radiotherapy","volume":"385","author":"Shaikh","year":"2015","journal-title":"Lancet"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.3390\/cancers13122980","article-title":"Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models During Serial Transplantation","volume":"13","author":"Pardo-S\u00e1nchez","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01181","article-title":"Prognostic Value of Vimentin Is Associated With Immunosuppression in Metastatic Renal Cell Carcinoma","volume":"10","author":"Yao","year":"2020","journal-title":"Front Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.cell.2011.11.016","article-title":"Cancer Invasion and the Microenvironment: Plasticity and Reciprocity","volume":"147","author":"Friedl","year":"2011","journal-title":"Cell"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486","article-title":"Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e1002731","DOI":"10.1080\/2162402x.2014.1002731","article-title":"The Mutually Regulatory Loop of Epithelial-Mesenchymal Transition and Immunosuppression in Cancer Progression","volume":"4","author":"Chen","year":"2015","journal-title":"Oncoimmunology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1615\/critrevimmunol.2014010183","article-title":"Tumor Plasticity Interferes With Anti-Tumor Immunity","volume":"34","author":"Chouaib","year":"2014","journal-title":"Crit Rev Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.3390\/cells9041040","article-title":"E-Cadherin in Pancreatic Ductal Adenocarcinoma: A Multifaceted Actor During EMT","volume":"9","author":"Sommariva","year":"2020","journal-title":"Cells"},{"key":"B54","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s13046-018-0981-2","article-title":"The Epithelial-to-Mesenchymal Transition Induced by Tumor-Associated Macrophages Confers Chemoresistance in Peritoneally Disseminated Pancreatic Cancer","volume":"37","author":"Kuwada","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28736","article-title":"Tumor-Associated Macrophages Exhibit Pro- and Anti-Inflammatory Properties by Which They Impact on Pancreatic Tumorigenesis","volume":"135","author":"Helm","year":"2014","journal-title":"Int J Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2019.02.003","article-title":"Targeting Tumor-Associated Macrophages in Cancer","volume":"40","author":"Pathria","year":"2019","journal-title":"Trends Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-015-1373-0","article-title":"Tumor-Associated Macrophages in Cancers","volume":"18","author":"Hu","year":"2016","journal-title":"Clin Transl Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib Tablets as Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a BRCA1\/2 Mutation (SOLO2\/ENGOT-Ov21): A Final Analysis of a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30324-7","article-title":"Olaparib and Durvalumab in Patients With Germline BRCA-Mutated Metastatic Breast Cancer (MEDIOLA): An Open-Label, Multicentre, Phase 1\/2, Basket Study","volume":"21","author":"Domchek","year":"2020","journal-title":"Lancet Oncol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1186\/s12885-020-07253-x","article-title":"Precision Medicine Phase II Study Evaluating the Efficacy of a Double Immunotherapy by Durvalumab and Tremelimumab Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes Mutation in Response or Stable After Olaparib Treatment","volume":"20","author":"Fumet","year":"2020","journal-title":"BMC Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s40425-018-0463-2","article-title":"Activity of Durvalumab Plus Olaparib in Metastatic Castration-Resistant Prostate Cancer in Men With and Without DNA Damage Repair Mutations","volume":"6","author":"Karzai","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-20-0056","article-title":"Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: A Proof-Of-Concept Phase II Study","volume":"26","author":"Lampert","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/s1470-2045(19)30689-8","article-title":"Atezolizumab Plus Nab-Paclitaxel as First-Line Treatment for Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer (IMpassion130): Updated Efficacy Results From a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.693881\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T05:31:37Z","timestamp":1630906297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.693881\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,6]]},"references-count":65,"alternative-id":["10.3389\/fimmu.2021.693881"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.693881","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,6]]},"article-number":"693881"}}